Hauben et al. [23] reported a marked increase in the number of spontaneous reports of hyperkalemia with spironolactone and the PRR EB05 since the publication of the RALE study, which indicated that an increased risk of serious hypercalemia occurred with the combination of spironolactone and ACE inhibitors. Here, ACE is linked to Hyperkalemia.